Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

BET domain co-regulators in obesity, inflammation and cancer.

Belkina AC, Denis GV.

Nat Rev Cancer. 2012 Jun 22;12(7):465-77. doi: 10.1038/nrc3256. Review.

2.

BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.

Belkina AC, Nikolajczyk BS, Denis GV.

J Immunol. 2013 Apr 1;190(7):3670-8. doi: 10.4049/jimmunol.1202838. Epub 2013 Feb 18.

3.

Selective inhibition of BET bromodomains.

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE.

Nature. 2010 Dec 23;468(7327):1067-73. doi: 10.1038/nature09504. Epub 2010 Sep 24.

4.

Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.

Padmanabhan B, Mathur S, Manjula R, Tripathi S.

J Biosci. 2016 Jun;41(2):295-311. Review.

5.

You bet-cha: a novel family of transcriptional regulators.

Florence B, Faller DV.

Front Biosci. 2001 Aug 1;6:D1008-18. Review.

PMID:
11487468
6.

BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.

Kokkola T, Suuronen T, Pesonen M, Filippakopoulos P, Salminen A, Jarho EM, Lahtela-Kakkonen M.

Chembiochem. 2015 Sep 21;16(14):1997-2001. doi: 10.1002/cbic.201500272. Epub 2015 Aug 13.

7.

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.

Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, Balansay B, Yu F, Oh S, Woo P, Chen S, Ponnuswami A, Monje M, Atwood SX, Whitson RJ, Mitra S, Cheshier SH, Qi J, Beroukhim R, Tang JY, Wechsler-Reya R, Oro AE, Link BA, Bradner JE, Cho YJ.

Nat Med. 2014 Jul;20(7):732-40. doi: 10.1038/nm.3613. Epub 2014 Jun 29.

8.

BET Bromodomain as a Target of Epigenetic Therapy.

Noguchi-Yachide T.

Chem Pharm Bull (Tokyo). 2016;64(6):540-7. doi: 10.1248/cpb.c16-00225. Review.

9.

Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.

Qi J.

Cold Spring Harb Perspect Biol. 2014 Dec 1;6(12):a018663. doi: 10.1101/cshperspect.a018663. Review.

10.
11.

Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.

Sartor GC, Powell SK, Brothers SP, Wahlestedt C.

J Neurosci. 2015 Nov 11;35(45):15062-72. doi: 10.1523/JNEUROSCI.0826-15.2015.

12.

The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

Shi J, Vakoc CR.

Mol Cell. 2014 Jun 5;54(5):728-36. doi: 10.1016/j.molcel.2014.05.016. Review.

13.

Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.

Xiao Y, Liang L, Huang M, Qiu Q, Zeng S, Shi M, Zou Y, Ye Y, Yang X, Xu H.

Rheumatology (Oxford). 2016 Jan;55(1):173-84. doi: 10.1093/rheumatology/kev312. Epub 2015 Aug 31.

PMID:
26324948
14.

Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes.

Wang F, Deeney JT, Denis GV.

Vitam Horm. 2013;91:49-75. doi: 10.1016/B978-0-12-407766-9.00003-1. Review.

15.

Targeting BET bromodomains for cancer treatment.

Jung M, Gelato KA, Fernández-Montalván A, Siegel S, Haendler B.

Epigenomics. 2015;7(3):487-501. doi: 10.2217/epi.14.91. Review.

PMID:
26077433
16.

Bromodomains: Structure, function and pharmacology of inhibition.

Ferri E, Petosa C, McKenna CE.

Biochem Pharmacol. 2016 Apr 15;106:1-18. doi: 10.1016/j.bcp.2015.12.005. Epub 2015 Dec 18. Review.

PMID:
26707800
17.

Histone modifications in transcriptional activation during plant development.

Berr A, Shafiq S, Shen WH.

Biochim Biophys Acta. 2011 Oct;1809(10):567-76. doi: 10.1016/j.bbagrm.2011.07.001. Epub 2011 Jul 14. Review.

PMID:
21777708
18.

BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.

Nicholas DA, Andrieu G, Strissel KJ, Nikolajczyk BS, Denis GV.

Cell Mol Life Sci. 2017 Jan;74(2):231-243. doi: 10.1007/s00018-016-2320-0. Epub 2016 Aug 4. Review.

PMID:
27491296
19.

The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites.

De Rijck J, de Kogel C, Demeulemeester J, Vets S, El Ashkar S, Malani N, Bushman FD, Landuyt B, Husson SJ, Busschots K, Gijsbers R, Debyser Z.

Cell Rep. 2013 Nov 27;5(4):886-94. doi: 10.1016/j.celrep.2013.09.040. Epub 2013 Oct 31.

20.

Supplemental Content

Support Center